A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma

Details

Language :

English

Volume :

5

Issue :

5

Database :

Complementary Index

Journal :

EJHaem

Publication Type :

Academic Journal

Accession number :

180280211

Full Text :

https://doi.org/10.1002/jha2.968